We bring the fight to bacteria

The WHO has declared that AMR is one of the top 10 global public health threats facing humanity and our unified economic structures. Felix recognizes that now is the moment to tackle this crucial problem.

What we do

Design and deploy phages to kill life threatening bacterial infections.

Why we do it

Protect the world against the coming threat of antimicrobial resistance.

How we do it

Produce programmable therapies that harness the power of evolution to kill resistant bacteria.

Progress

Our version 1.0 asset treating Pseudomonas aeruginosa infections in cystic fibrosis patients has been used in patients (like Paige) and is currently being tested in a controlled, blinded clinical trial.

Our treatment has shown the potential to improve lung function, decrease lung microbial load and, in many cases, decrease bacterial virulence.

Paige Rogers – survived an antimicrobial resistant lung infection with the help of our Phage 1.0 treatment

Our Mission

A global challenge requires accessible medicines.

Antimicrobial resistance is a growing global threat endangering healthcare systems and economic prosperity if unchecked. The majority of phage therapies under development are personalized, expensive, and difficult to scale. From day one, our approach has been to create generalized, broadly applicable phage therapies - treatments that could be shipped around the world and administered as easily as a pill.

A patient being examined by a doctor

Felix Team

Our team is inspired to solve the challenge of life-threatening resistant infections using our unique combination of passion and knowledge about phage, phage-antibiotic combinations and our advanced platform supporting analysis of genotypes and phenotypes at scale.

Team

Robert McBride, PhD
Robert McBride, PhD
Co-Founder & Chief Executive Officer
Natalie Ma, PhD
Natalie Ma, PhD
Co-Founder & Business Development
Joel Berry, PhD
Joel Berry, PhD
Principal Scientist
Agnès Oromí Bosch, MS
Agnès Oromí Bosch, MS
Associate Scientist
Max Hopkins, MS
Max Hopkins, MS
Associate Scientist
Hemaa Selvakumar
Hemaa Selvakumar
Scientist

Scientific Advisory Board

Jennifer Doudna
Jennifer Doudna
Professor  
UC Berkeley
Paul Turner, PhD
Paul Turner, PhD
Scientific Co-Founder
Yale University
Stephanie Strathdee
Stephanie Strathdee
Professor (uncompensated)
UC San Diego
Rodolphe Barrangou
Rodolphe Barrangou
Professor
North Carolina State University
Adam Deutschbauer
Adam Deutschbauer
Adjunct Assistant Professor
UC Berkeley
Ben Chan
Ben Chan
Scientist (uncompensated)
Yale University
Adam Arkin, PhD
Adam Arkin, PhD
Scientific Co-Founder
UC Berkeley
Prabhavathi Fernandes
Prabhavathi Fernandes
Chair of the SAC
GARDP
Matthew Sullivan
Matthew Sullivan
Professor of Microbiology
Ohio State University
Vivek Mutalik, PhD
Vivek Mutalik, PhD
Scientific Co-Founder
Berkeley Lab
Max Leabo
Max Leabo
Scientist, Patient
Celsius Therapeutics
Jon Koff, MD
Jon Koff, MD
Ass. Professor (uncompensated)
Yale School of Medicine

Ready to join the team?

We’re building a technical team of scientists and engineers who are passionate about working on world-saving problems.

Careers